|
Cancer origin
|
Biologics
|
SIR (95%
CI)
|
nbDMARDs
|
SIR (95%
CI)
|
|---|
| |
N
|
Expected
| |
N
|
Expected
| |
|---|
|
Non-hematologic cancers
|
73
|
88.46
|
0.83 (0.65, 1.04)
|
455
|
347.47
|
1.31 (1.19, 1.44)
|
|
Oral cavity
|
2
|
4.55
|
0.44 (0.05, 1.59)
|
20
|
17.92
|
1.12 (0.68, 1.72)
|
|
Digestive system1
|
20
|
32.03
|
0.62 (0.38, 0.97)
|
135
|
125.75
|
1.07 (0.90, 1.27)
|
|
Lungs2
|
11
|
10.39
|
1.06 (0.53, 1.89)
|
57
|
40.77
|
1.40 (1.06, 1.81)
|
|
Breast, cervix3
|
22
|
19.96
|
1.10 (0.69, 1.67)
|
115
|
78.45
|
1.47 (1.21, 1.76)
|
|
Bladder/kidney4
|
14
|
15.75
|
0.89 (0.49, 1.49)
|
96
|
61.81
|
1.55 (1.26, 1.90)
|
|
Melanoma
|
0
|
0.21
|
-
|
0
|
0.83
|
-
|
|
NMSC
|
5
|
2.43
|
2.05 (0.66, 4.79)
|
15
|
9.58
|
1.57 (0.88, 2.58)
|
|
Unspecified origin
|
4
|
5.79
|
0.69 (0.19, 1.77)
|
32
|
22.76
|
1.41 (0.96, 1.99)
|
|
Hematologic cancers
5
|
16
|
3.45
|
4.64 (2.65, 7.53)
|
31
|
13.57
|
2.28 (1.55, 3.24)
|
|
Lymphoma
|
13
|
2.12
|
6.13 (3.26, 10.49)
|
21
|
8.34
|
2.52 (1.56, 3.85)
|
|
NHL
|
12
|
2.05
|
5.86 (3.02, 10.24)
|
20
|
8.06
|
2.48 (1.52, 3.83)
|
|
HL
|
1
|
0.07
|
13.97 (0.18, 77.7)
|
1
|
0.28
|
3.56 (0.05, 19.79)
|
|
Leukemia
|
1
|
1.33
|
0.75 (0.01, 4.18)
|
9
|
5.23
|
1.72 (0.79, 3.27)
|
-
1Cancers of digestive system include cancers of the stomach, colon, liver, pancreas. 2Including cancers of the lungs, bronchus and pleura. 3Including cancers of the uterus and other female reproductive organs. 4Including cancers of the prostate, testis and other male reproductive organs. 5Myeloma not included. NbDARDS, nonbiologic disease-modifying anti-rheumatic drugs; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; NMSC, non-melanoma skin cancers; N, number.
